ArticleRheumatology (Oxford, England)2025

Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase.

Orrin M Troum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.